EQS (Equus Total Return, Inc.) Stock Analysis - News
Equus Total Return, Inc. (EQS) is a publicly traded Financial Services sector company. As of May 21, 2026, EQS trades at $1.33 with a market cap of $18.86M and a P/E ratio of 0.00. EQS moved +9.64% today. Year to date, EQS is -10.20%; over the trailing twelve months it is +60.57%. Its 52-week range spans $0.74 to $2.49. Rallies surfaces EQS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in EQS news today?
Equus NAV Drops to $1.19 Driven by $12.35M Morgan E&P Write-Down: Equus Total Return reported net assets of $16.6 million as of December 31, 2025, down from $26.5 million at September 30, 2025, driving NAV per share to $1.19 from $1.90. A $12.35 million write-down at Morgan E&P due to lower oil forward curves and reserve eliminations partially offset by a $1.6 million valuation gain on CitroTech holdings narrowed the NAV.
KNAUSS ROBERT L bought 1.00K (~$1.48K) on Jul 14, 2023.
des Pallieres Bertrand sold 1.84M (~$4.43M) on Sep 29, 2021.
Atkinson Fraser bought 4.03K (~$7.62K) on Apr 29, 2021.
EQS Analyst Consensus
EQS analyst coverage data. Average price target: $0.00.
Common questions about EQS
What changed in EQS news today?
Equus NAV Drops to $1.19 Driven by $12.35M Morgan E&P Write-Down: Equus Total Return reported net assets of $16.6 million as of December 31, 2025, down from $26.5 million at September 30, 2025, driving NAV per share to $1.19 from $1.90. A $12.35 million write-down at Morgan E&P due to lower oil forward curves and reserve eliminations partially offset by a $1.6 million valuation gain on CitroTech holdings narrowed the NAV.
Does Rallies summarize EQS news?
Yes. Rallies summarizes EQS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is EQS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for EQS. It does not provide personalized investment advice.
